A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.

A new patient advocacy organization, the ApoE4 Alzheimer’s Alliance, has launched in the U.S., with a goal of helping advance both supportive policies and the development of treatments for people with ...

Cassava will stop developing simufilam for Alzheimer’s this year after a Phase 3 trial failed to improve cognition and daily function.

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...

Winter in a cold climate can add challenges when caregiving for someone with dementia, columnist Ray Burow writes.

Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease.

Sage plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s after it failed to boost cognitive function in a Phase 2 study.

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease ...

A total of 1,929 Alzheimer's patients have enrolled in two simufilam studies, which the FDA said could support its application for approval.

The FDA has approved BrainSee, a software for predicting Alzheimer's dementia in people with mild cognitive impairments.

NE3107, an experimental oral therapy, fared well in a Phase 3 trial of people with mild-to-moderate Alzheimer’s, despite protocol deviations.